Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:769 |
Name | neuroblastoma |
Definition | An autonomic nervous system neoplasm that derives_from immature nerve cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer peripheral nervous system neoplasm autonomic nervous system neoplasm neuroblastoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT00089245 | Phase I | Omburtamab I-131 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | Terminated | USA | 0 |
NCT00601003 | Phase II | Cyclophosphamide + Nifurtimox + Topotecan | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | Completed | USA | 0 |
NCT00602667 | Phase I | Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan | Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma | Active, not recruiting | USA | AUS | 0 |
NCT00885326 | Phase I | Bevacizumab + Cyclophosphamide + Zoledronic acid | N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma | Completed | USA | CAN | 0 |
NCT00911560 | Phase Ib/II | Beta-glucan GD2-GD3 vaccine | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral beta-glucan for High-Risk Neuroblastoma | Active, not recruiting | USA | 0 |
NCT00939770 | Phase Ib/II | Crizotinib | Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | USA | CAN | 0 |
NCT01175356 | Phase I | Busulfan + Melphalan Cyclophosphamide + Topotecan 131I-MIBG Cyclophosphamide + Doxorubicin + Vincristine Sulfate Cisplatin + Etoposide | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | Active, not recruiting | USA | 0 |
NCT01241162 | Phase I | Decitabine | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | Completed | USA | 0 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01492673 | Phase II | Bevacizumab + Cyclophosphamide + Topotecan | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma | Completed | USA | CAN | 0 |
NCT01518413 | Phase I | Irinotecan + Sorafenib | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Completed | USA | 0 |
NCT01526603 | Phase I | Melphalan Etoposide Filgrastim Tretinoin Carboplatin | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | Completed | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01601535 | Phase Ib/II | Alisertib + Irinotecan + Temozolomide | Study of MLN8237 in Combination With Irinotecan and Temozolomide | Completed | USA | CAN | 0 |
NCT01625351 | Phase I | Fludarabine Melphalan Busulfan Alemtuzumab | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01704716 | Phase III | Busulfan + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Filgrastim Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Dinutuximab beta Aldesleukin + Dinutuximab beta Carboplatin + Etoposide + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | Recruiting | SWE | SVN | SVK | POL | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CZE | CHE | BEL | AUT | AUS | 1 |
NCT01747876 | Phase I | Ribociclib | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | Terminated | USA | GBR | FRA | DEU | AUS | 0 |
NCT01757626 | Phase Ib/II | Naxitamab + Sargramostim | Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | Active, not recruiting | USA | 0 |
NCT01767194 | Phase II | Dinutuximab Temsirolimus Irinotecan + Temozolomide | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | Completed | USA | NZL | CAN | AUS | 1 |
NCT01822652 | Phase I | Cyclophosphamide Fludarabine Pembrolizumab | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | Active, not recruiting | USA | 0 |
NCT01838187 | Expanded access | Vorinostat | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | No longer available | USA | 0 |
NCT01857934 | Phase II | Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan | Therapy for Children With Advanced Stage Neuroblastoma | Active, not recruiting | USA | 0 |
NCT01956669 | Phase II | Pazopanib | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | Completed | USA | SVK | HUN | FRA | ESP | CZE | CAN | 0 |
NCT02013336 | Phase I | Cyclophosphamide + Liposomal irinotecan | Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors | Unknown status | USA | 0 |
NCT02030964 | Phase I | Cyclophosphamide + Topotecan Celecoxib | N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan | Active, not recruiting | USA | CAN | AUS | 0 |
NCT02035137 | Phase II | 131I-MIBG 131I-MIBG + Irinotecan + Vincristine Sulfate 131I-MIBG + Vorinostat | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat (N2011-01) | Completed | USA | CAN | 0 |
NCT02075177 | Phase I | Ketoconazole Fenretinide | Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | No longer available | USA | 0 |
NCT02095132 | Phase Ib/II | Adavosertib + Irinotecan | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT02100891 | Phase II | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | Completed | USA | 0 | |
NCT02124772 | Phase I | Trametinib Dabrafenib + Trametinib | Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations | Completed | USA | GBR | FRA | CAN | AUS | 0 |
NCT02130869 | Phase I | Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT02139397 | Phase Ib/II | Eflornithine Bortezomib | Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma | Completed | USA | 0 |
NCT02163356 | Phase I | Vincristine Sulfate Fenretinide Ketoconazole | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma | Terminated | USA | 0 |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02298348 | Phase I | Cyclophosphamide + Sorafenib + Topotecan | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | Active, not recruiting | USA | CAN | 0 |
NCT02303028 | Phase Ib/II | Pazopanib + Topotecan | Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours | Completed | CAN | 0 |
NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Completed | USA | CAN | 0 |
NCT02308527 | Phase II | Bevacizumab + Irinotecan + Temozolomide Temozolomide + Topotecan Bevacizumab + Temozolomide Bevacizumab + Temozolomide + Topotecan Dinutuximab beta + Temozolomide Temozolomide Dinutuximab beta + Temozolomide + Topotecan Irinotecan + Temozolomide Cyclophosphamide + Dinutuximab beta + Topotecan | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children (BEACON) | Active, not recruiting | NLD | ITA | IRL | GBR | FRA | ESP | DNK | CHE | BEL | AUT | 0 |
NCT02311621 | Phase I | CE7R CAR-T cells | Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | Active, not recruiting | USA | 0 |
NCT02337309 | Phase I | SF1126 | SF1126 for Patients With Relapsed or Refractory Neuroblastoma | Terminated | USA | 0 |
NCT02372006 | Phase Ib/II | Afatinib | Trial of Afatinib in Pediatric Tumours | Completed | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUT | AUS | 1 |
NCT02378428 | Phase II | 131I-MIBG | MIBG Therapy for Patients With MIBG Avid Tumors | Active, not recruiting | USA | 0 |
NCT02508038 | Phase I | Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa | Recruiting | USA | 0 |
NCT02559778 | Phase I | Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) | Recruiting | USA | CAN | 0 |
NCT02573896 | Phase I | Dinutuximab + Lenalidomide | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | Active, not recruiting | USA | 0 |
NCT02574728 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | Recruiting | USA | 0 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | 0 |
NCT02644460 | Phase I | Abemaciclib | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Completed | USA | 0 |
NCT02650401 | Phase I | Entrectinib | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 4 |
NCT02650648 | Phase I | Aldesleukin + Cyclophosphamide + Naxitamab | Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | Active, not recruiting | USA | 0 |
NCT02748135 | Phase Ib/II | TB-403 | A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma | Completed | USA | 0 |
NCT02780128 | Phase I | Siremadlin Ceritinib + Ribociclib Trametinib | Next Generation Personalized Neuroblastoma Therapy | Terminated | USA | 0 |
NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Active, not recruiting | USA | 0 |
NCT02909777 | Phase I | CUDC-907 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | Active, not recruiting | USA | 0 |
NCT02914405 | Phase I | Dinutuximab beta + Nivolumab Nivolumab | Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma (MiniVan) | Active, not recruiting | USA | GBR | 0 |
NCT02982941 | Phase I | MGA271 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Completed | USA | 0 |
NCT03033303 | Phase II | Isotretinoin + Naxitamab + Sargramostim | A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma | Active, not recruiting | USA | 0 |
NCT03107988 | Phase I | Cyclophosphamide + Lorlatinib + Topotecan Lorlatinib | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | Active, not recruiting | USA | GBR | FRA | CAN | 0 |
NCT03126916 | Phase III | Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Active, not recruiting | USA | CAN | 1 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03189706 | Phase I | Irinotecan + Naxitamab + Sargramostim + Temozolomide | Study of Chemoimmunotherapy for High-Risk Neuroblastoma | Active, not recruiting | USA | 0 |
NCT03209869 | Phase I | hu14.18-IL2 | Treatment of Relapsed or Refractory Neuroblastoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 | Withdrawn | USA | 0 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213652 | Phase II | Ensartinib | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03213678 | Phase II | LY3023414 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213691 | Phase II | Selumetinib | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03233204 | Phase II | Olaparib | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | Completed | USA | 1 |
NCT03275402 | Phase II | Omburtamab I-131 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | Terminated | USA | ESP | DNK | 1 |
NCT03332667 | Phase I | 131I-MIBG + Dinutuximab + Sargramostim + Vorinostat 131I-MIBG + Dinutuximab + Sargramostim | MIBG With Dinutuximab +/- Vorinostat | Active, not recruiting | USA | 0 |
NCT03363373 | Phase III | Naxitamab + Sargramostim | Naxitamab for Neuroblastoma With Osteomedullary Disease | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | 1 |
NCT03373097 | Phase Ib/II | GD2-CART01 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | Recruiting | ITA | 0 |
NCT03458728 | Phase Ib/II | Copanlisib | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Terminated | USA | 0 |
NCT03478462 | Phase I | CLR 131 | Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | Active, not recruiting | USA | CAN | AUS | 0 |
NCT03526250 | Phase II | Palbociclib | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | Completed | USA | 1 |
NCT03561259 | Phase II | 131I-MIBG + Vorinostat 131I-MIBG | A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM) | Recruiting | USA | 0 |
NCT03581240 | Expanded access | Eflornithine | An Intermediate Expanded Use Trial of DFMO | Available | USA | 0 |
NCT03585465 | Phase Ib/II | Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Cyclophosphamide + Vinblastine Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Nivolumab | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors | Active, not recruiting | FRA | BEL | 0 |
NCT03635632 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Active, not recruiting | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03709680 | Phase I | Irinotecan + Palbociclib + Temozolomide | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | Active, not recruiting | USA | TUR | SWE | SVK | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | ARG | 2 |
NCT03721068 | Phase I | iC9.GD2.CAR.IL-15 T-cells Cyclophosphamide + Fludarabine | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma | Recruiting | USA | 0 |
NCT03786783 | Phase II | Isotretinoin Cyclophosphamide + Thiotepa Cisplatin + Dinutuximab + Etoposide + Sargramostim Cyclophosphamide + Dinutuximab + Doxorubicin + Sargramostim + Vincristine Sulfate Dexrazoxane Cyclophosphamide + Topotecan Dinutuximab + Isotretinoin + Sargramostim Carboplatin + Etoposide + Melphalan | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | Active, not recruiting | USA | NZL | AUS | 0 |
NCT03794349 | Phase II | Dinutuximab + Irinotecan + Sargramostim + Temozolomide Dinutuximab + Eflornithine + Irinotecan + Sargramostim + Temozolomide | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT03838042 | Phase Ib/II | Entinostat + Nivolumab | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) | Recruiting | SWE | NLD | FRA | DEU | CHE | AUT | AUS | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
NCT04029688 | Phase Ib/II | Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | Completed | USA | NLD | GBR | FRA | ESP | CAN | 0 |
NCT04106219 | Phase I | LY3295668 Cyclophosphamide + LY3295668 + Topotecan | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT04211675 | Phase Ib/II | Dinutuximab + Irinotecan + Sargramostim + Temozolomide | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING) | Recruiting | USA | 0 |
NCT04221035 | Phase III | Busulfan + Melphalan + Thiotepa Dinutuximab beta Cisplatin + Etoposide + Vindesine Dacarbazine + Doxorubicin + Ifosfamide + Vincristine Sulfate Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate Busulfan + Melphalan | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) | Recruiting | SWE | SVN | SVK | NOR | NLD | LTU | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | BEL | AUS | 0 |
NCT04239040 | Phase I | GVAX + Ipilimumab + Nivolumab | GVAX Plus Checkpoint Blockade in Neuroblastoma | Active, not recruiting | USA | 0 |
NCT04284774 | Phase II | Tipifarnib | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | Active, not recruiting | USA | 1 |
NCT04301843 | Phase II | Eflornithine + Etoposide | Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | Recruiting | USA | CAN | 0 |
NCT04385277 | Phase II | Dinutuximab + Irinotecan + Isotretinoin + Sargramostim + Temozolomide | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | Active, not recruiting | USA | NZL | CAN | AUS | 0 |
NCT04500548 | Phase I | Nivolumab Ipilimumab + Nivolumab | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | Withdrawn | USA | CAN | 0 |
NCT04501757 | Expanded access | Naxitamab + Sargramostim | Naxitamab and GM-CSF in People With Neuroblastoma | No longer available | USA | 0 |
NCT04544995 | Phase I | Dostarlimab-gxly + Niraparib | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors | Recruiting | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
NCT04560166 | Phase II | Irinotecan + Naxitamab + Sargramostim + Temozolomide | Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma | Terminated | 2 | |
NCT04730349 | Phase Ib/II | Nivolumab + NKTR-214 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) | Terminated | USA | ITA | FRA | ESP | DEU | AUS | 0 |
NCT04751383 | Phase I | Dinutuximab + Hu5F9-G4 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | Terminated | USA | CAN | 0 |
NCT04897880 | Phase II | Panobinostat | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH) | Terminated | USA | NZL | AUS | 0 |
NCT05004116 | Phase Ib/II | Irinotecan + Repotrectinib + Temozolomide | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | Recruiting | USA | 0 |
NCT05064306 | Expanded access | Omburtamab I-131 | 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults | Available | USA | 0 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05421897 | FDA approved | Cyclophosphamide + Dinutuximab + Irinotecan + Sargramostim + Temozolomide + Topotecan | Rapid Administration Pilot for Infusing Dinutuximab (RAPID) | Suspended | USA | 0 |
NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT05489887 | Phase II | Ceritinib + Naxitamab Naxitamab | Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Recruiting | USA | CAN | 0 |
NCT05650749 | Phase I | GPC2 CAR-T cells | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (GPC2) | Recruiting | USA | 0 |
NCT05990751 | Phase I | GD2 CAR T cells | Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma (MAGNETO) | Recruiting | GBR | 0 |
NCT06047977 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + tumor infiltrating lymphocytes | Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Not yet recruiting | USA | 0 |
NCT06172296 | Phase III | Cyclophosphamide + Topotecan Cisplatin + Etoposide Dinutuximab + Irinotecan + Temozolomide Cisplatin + Dinutuximab + Etoposide Dinutuximab beta + Temozolomide Cisplatin + Cyclophosphamide + Dexrazoxane + Dinutuximab + Doxorubicin + Etoposide + Topotecan + Vincristine Sulfate Dinutuximab + Isotretinoin Carboplatin + Cyclophosphamide + Etoposide + Melphalan + Thiotepa Cisplatin + Cyclophosphamide + Dexrazoxane + Doxorubicin + Etoposide + Topotecan + Vincristine Sulfate | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Recruiting | USA | NZL | CAN | AUS | 0 |
NCT06380816 | Phase Ib/II | UCB4594 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Recruiting | GBR | 0 |
NCT06395103 | Phase Ib/II | VLS-101 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Recruiting | USA | ISR | GBR | ESP | BRA | 2 |
NCT06450041 | Phase II | Dinutuximab + Irinotecan + Sargramostim + Temozolomide + TGF-beta-imprinted NK cells | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | Recruiting | USA | 0 |
NCT06485947 | Phase I | Carboplatin + Cisplatin + Cyclophosphamide + Dinutuximab beta + Etoposide + Vincristine Sulfate Cisplatin + Dinutuximab beta + Etoposide + Vindesine Dacarbazine + Dinutuximab beta + Doxorubicin + Ifosfamide + Vincristine Sulfate | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma (DBPilot) | Not yet recruiting | NLD | 0 |
NCT06528496 | Phase II | Irinotecan Doxorubicin Ifosfamide Sargramostim Etoposide Temozolomide Carboplatin Naxitamab Vincristine Sulfate Topotecan Cyclophosphamide | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | Recruiting | USA | 0 |
NCT06540963 | Phase II | Naxitamab + Tipifarnib | Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma | Recruiting | USA | 0 |
NCT06541262 | Phase Ib/II | Irinotecan + Silmitasertib + Temozolomide + Vincristine Sulfate Irinotecan + Silmitasertib + Temozolomide | Silmitasertib (CX-4945) in Combination with Chemotherapy for Relapsed Refractory Solid Tumors | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |